Cargando…

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

AIMS: This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF) >40% varied by baseline New York Heart Association (NYHA) class and examined the treatment effects on NYHA class over tim...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostrominski, John W., Vaduganathan, Muthiah, Claggett, Brian L., de Boer, Rudolf A., Desai, Akshay S., Dobreanu, Dan, Hernandez, Adrian F., Inzucchi, Silvio E., Jhund, Pardeep S., Kosiborod, Mikhail, Lam, Carolyn S.P., Langkilde, Anna M., Lindholm, Daniel, Martinez, Felipe A., O'Meara, Eileen, Petersson, Magnus, Shah, Sanjiv J., Thierer, Jorge, McMurray, John J.V., Solomon, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804680/
https://www.ncbi.nlm.nih.gov/pubmed/36054231
http://dx.doi.org/10.1002/ejhf.2652
_version_ 1784862165240381440
author Ostrominski, John W.
Vaduganathan, Muthiah
Claggett, Brian L.
de Boer, Rudolf A.
Desai, Akshay S.
Dobreanu, Dan
Hernandez, Adrian F.
Inzucchi, Silvio E.
Jhund, Pardeep S.
Kosiborod, Mikhail
Lam, Carolyn S.P.
Langkilde, Anna M.
Lindholm, Daniel
Martinez, Felipe A.
O'Meara, Eileen
Petersson, Magnus
Shah, Sanjiv J.
Thierer, Jorge
McMurray, John J.V.
Solomon, Scott D.
author_facet Ostrominski, John W.
Vaduganathan, Muthiah
Claggett, Brian L.
de Boer, Rudolf A.
Desai, Akshay S.
Dobreanu, Dan
Hernandez, Adrian F.
Inzucchi, Silvio E.
Jhund, Pardeep S.
Kosiborod, Mikhail
Lam, Carolyn S.P.
Langkilde, Anna M.
Lindholm, Daniel
Martinez, Felipe A.
O'Meara, Eileen
Petersson, Magnus
Shah, Sanjiv J.
Thierer, Jorge
McMurray, John J.V.
Solomon, Scott D.
author_sort Ostrominski, John W.
collection PubMed
description AIMS: This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF) >40% varied by baseline New York Heart Association (NYHA) class and examined the treatment effects on NYHA class over time. METHODS AND RESULTS: Treatment effects of dapagliflozin by baseline NYHA class II (n = 4713) versus III/IV (n = 1549) were examined on the primary endpoint (cardiovascular death or worsening HF event) and key secondary endpoints. Effects of dapagliflozin on change in NYHA class at 4, 16, and 32 weeks were also evaluated. Higher baseline NYHA class was associated with older age, female sex, greater comorbidity burden, lower LVEF, and higher natriuretic peptide levels. Participants with baseline NYHA class III/IV, as compared with II, were independently more likely to experience the primary endpoint (adjusted hazard ratio [HR] 1.16 [95% confidence interval, 1.02–1.33]) and all‐cause death (adjusted HR 1.22 [1.06–1.40]). Dapagliflozin consistently reduced the risk of the primary endpoint compared with placebo, irrespective of baseline NYHA class (HR 0.81 [0.70–0.94] for NYHA class II vs. HR 0.80 [0.65–0.98] for NYHA class III/IV; p (interaction) = 0.921). Participants with NYHA class III/IV had greater improvement in Kansas City Cardiomyopathy Questionnaire total symptom scores between baseline and 32 weeks (+4.8 [2.5–7.1]) versus NYHA class II (+1.8 [0.7–2.9]; p (interaction) = 0.011). Dapagliflozin was associated with higher odds of any improvement in NYHA class (odds ratio [OR] 1.32 [1.16–1.51]), as well as improvement to NYHA class I (OR 1.43 [1.17–1.75]), versus placebo at 32 weeks, with benefits seen as early as 4 weeks. CONCLUSIONS: Among symptomatic patients with HF and LVEF >40%, treatment with dapagliflozin provided clinical benefit irrespective of baseline NYHA class and was associated with early and sustained improvements in NYHA class over time.
format Online
Article
Text
id pubmed-9804680
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Ltd.
record_format MEDLINE/PubMed
spelling pubmed-98046802023-01-06 Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial Ostrominski, John W. Vaduganathan, Muthiah Claggett, Brian L. de Boer, Rudolf A. Desai, Akshay S. Dobreanu, Dan Hernandez, Adrian F. Inzucchi, Silvio E. Jhund, Pardeep S. Kosiborod, Mikhail Lam, Carolyn S.P. Langkilde, Anna M. Lindholm, Daniel Martinez, Felipe A. O'Meara, Eileen Petersson, Magnus Shah, Sanjiv J. Thierer, Jorge McMurray, John J.V. Solomon, Scott D. Eur J Heart Fail Focused Issue on Clinical Trials AIMS: This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF) >40% varied by baseline New York Heart Association (NYHA) class and examined the treatment effects on NYHA class over time. METHODS AND RESULTS: Treatment effects of dapagliflozin by baseline NYHA class II (n = 4713) versus III/IV (n = 1549) were examined on the primary endpoint (cardiovascular death or worsening HF event) and key secondary endpoints. Effects of dapagliflozin on change in NYHA class at 4, 16, and 32 weeks were also evaluated. Higher baseline NYHA class was associated with older age, female sex, greater comorbidity burden, lower LVEF, and higher natriuretic peptide levels. Participants with baseline NYHA class III/IV, as compared with II, were independently more likely to experience the primary endpoint (adjusted hazard ratio [HR] 1.16 [95% confidence interval, 1.02–1.33]) and all‐cause death (adjusted HR 1.22 [1.06–1.40]). Dapagliflozin consistently reduced the risk of the primary endpoint compared with placebo, irrespective of baseline NYHA class (HR 0.81 [0.70–0.94] for NYHA class II vs. HR 0.80 [0.65–0.98] for NYHA class III/IV; p (interaction) = 0.921). Participants with NYHA class III/IV had greater improvement in Kansas City Cardiomyopathy Questionnaire total symptom scores between baseline and 32 weeks (+4.8 [2.5–7.1]) versus NYHA class II (+1.8 [0.7–2.9]; p (interaction) = 0.011). Dapagliflozin was associated with higher odds of any improvement in NYHA class (odds ratio [OR] 1.32 [1.16–1.51]), as well as improvement to NYHA class I (OR 1.43 [1.17–1.75]), versus placebo at 32 weeks, with benefits seen as early as 4 weeks. CONCLUSIONS: Among symptomatic patients with HF and LVEF >40%, treatment with dapagliflozin provided clinical benefit irrespective of baseline NYHA class and was associated with early and sustained improvements in NYHA class over time. John Wiley & Sons, Ltd. 2022-08-27 2022-10 /pmc/articles/PMC9804680/ /pubmed/36054231 http://dx.doi.org/10.1002/ejhf.2652 Text en © 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Focused Issue on Clinical Trials
Ostrominski, John W.
Vaduganathan, Muthiah
Claggett, Brian L.
de Boer, Rudolf A.
Desai, Akshay S.
Dobreanu, Dan
Hernandez, Adrian F.
Inzucchi, Silvio E.
Jhund, Pardeep S.
Kosiborod, Mikhail
Lam, Carolyn S.P.
Langkilde, Anna M.
Lindholm, Daniel
Martinez, Felipe A.
O'Meara, Eileen
Petersson, Magnus
Shah, Sanjiv J.
Thierer, Jorge
McMurray, John J.V.
Solomon, Scott D.
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
title Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
title_full Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
title_fullStr Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
title_full_unstemmed Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
title_short Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
title_sort dapagliflozin and new york heart association functional class in heart failure with mildly reduced or preserved ejection fraction: the deliver trial
topic Focused Issue on Clinical Trials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804680/
https://www.ncbi.nlm.nih.gov/pubmed/36054231
http://dx.doi.org/10.1002/ejhf.2652
work_keys_str_mv AT ostrominskijohnw dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT vaduganathanmuthiah dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT claggettbrianl dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT deboerrudolfa dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT desaiakshays dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT dobreanudan dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT hernandezadrianf dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT inzucchisilvioe dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT jhundpardeeps dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT kosiborodmikhail dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT lamcarolynsp dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT langkildeannam dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT lindholmdaniel dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT martinezfelipea dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT omearaeileen dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT peterssonmagnus dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT shahsanjivj dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT thiererjorge dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT mcmurrayjohnjv dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial
AT solomonscottd dapagliflozinandnewyorkheartassociationfunctionalclassinheartfailurewithmildlyreducedorpreservedejectionfractionthedelivertrial